外周动脉疾病腔内治疗后双功超声监测的回顾性队列研究
本研究在澳大利亚悉尼威尔士亲王医院回顾了2016至2017年因症状性外周动脉疾病接受股腘动脉腔内介入的连续患者,完成24个月随访。
要点
- 股腘动脉腔内治疗后24个月内复合终点发生率为37.5%。
- 该数据支持推进SURVEIL随机对照试验并为其设计提供依据。
核心结论
- 在当代队列中,目标血管闭塞、主要不良肢体事件或死亡的复合终点在24个月内发生于超过三分之一患者。
主要发现
- 间歇性跛行占62.5%,慢性肢体威胁性缺血占37.5%。
- TASC II病变分型:A型8.3%、B型35.4%、C型37.5%、D型18.8%。
- 治疗策略:单纯球囊扩张37.5%、球囊扩张加支架60.4%、1例(2.1%)接受斑块旋切辅助药物涂层球囊。
- 24个月内主要复合终点发生于18例患者(37.5%)。
临床怎么用
- 该队列数据可用于指导SURVEIL随机对照试验的入选标准、终点选择和样本量估算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative duplex ultrasound (DUS) surveillance is common practice globally, yet there is limited evidence to demonstrate its efficacy. This study aimed to determine the incidence of adverse events in a contemporary cohort of patients undergoing post endovascular therapy DUS surveillance and to inform the design of a planned randomized controlled trial. METHODS: A retrospective cohort study was conducted at Prince of Wales Hospital, Sydney, Australia. We reviewed consecutive patients who underwent endovascular intervention of the femoropopliteal arterial segment for symptomatic peripheral arterial disease between 2016 and 2017, with 24-month follow-up completed prior to coronavirus disease 2019 (COVID-19). The primary end point was a composite of target vessel occlusion, major adverse limb event (MALE), and/or death. RESULTS: Forty-eight patients met inclusion criteria. The mean age was 71.9 years (range 52-92), with 52.1% male. Indications included intermittent claudication (62.5%) and chronic limb-threatening ischemia (37.5%). Trans-Atlantic Inter-Society Consensus II (TASC II) lesion classifications were as follows: type A (8.3%), type B (35.4%), type C (37.5%), and type D (18.8%). Treatment strategies included angioplasty alone (37.5%), angioplasty with stenting (60.4%) and one patient (2.1%) who received atherectomy adjunctive to drug-coated ballooning. The primary composite end point occurred in 18 patients (37.5%) over 24 months. CONCLUSION: In this contemporary cohort, the composite end point of target vessel occlusion, MALE, or death occurred in over a third of patients within 24 months. These data support proceeding with the planned SURVEIL randomized controlled trial (ACTRN12625000889459p) and inform its eligibility criteria, end point selection, and sample size estimation.
引用
- Warburton TM, Thomas SD, Lennox AF, et al. Duplex Ultrasound Surveillance after Endovascular Therapy for Peripheral Arterial Disease: A Retrospective Cohort Study. Ann Vasc Surg. 2026. PMID: 42364765. doi:10.1016/j.avsg.2026.06.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。